% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Jabbarli:298903,
      author       = {L. Jabbarli and M. Fiorentzis and P. Rating and B. Schmidt
                      and E. Biewald and N. Guberina$^*$ and D. Flühs and N.
                      Bornfeld and W. Sauerwein and M. Stuschke$^*$ and N. E.
                      Bechrakis and M. Guberina$^*$},
      title        = {{F}unctional outcome after {B}rachytherapy with bi-nuclide
                      ({R}u-106/{I}odine-125) plaques in large uveal melanomas.},
      journal      = {Radiation oncology},
      volume       = {20},
      number       = {1},
      issn         = {1748-717X},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2025-00342},
      pages        = {22},
      year         = {2025},
      abstract     = {Preservation of visual acuity remains a challenging issue
                      after globe sparing therapy of large uveal melanoma. The aim
                      of our study was analyzing the functional outcome after
                      brachytherapy with bi-nuclide plaques (BBNP), maintaining
                      prognostic factors for legal blindness (LB).We have analyzed
                      all consecutive patients with large uveal melanoma treated
                      with BBNP at our institution between 01/1999 and 12/2020.
                      The post-treatment follow-up data were screened up to
                      06/2023. Univariate and multivariate Cox regression analysis
                      was performed to identify predictive factors for development
                      of LB following BBNP.Overall, 570 patients with median age
                      of 65.6 years (interquartile range [IQR]: 54.5-74.0)
                      underwent BBNP. During the median post-treatment follow-up
                      of 30.8 months (IQR: 12.9-57.3), LB was diagnosed in 287
                      $(50.4\%)$ patients. Patients' age (> 67 years, adjusted
                      hazard ratio [aHR] = 1.58, $95\%-confidence$ interval [CI] =
                      1.24-2.00, p < 0.0001), tumor thickness (> 8.5 mm, aHR =
                      1.43, $95\%-CI$ = 1.12-1.82, p = 0.004), VA (> 0.5 LogMAR,
                      aHR = 1.59, $95\%-CI$ = 1.25-2.02, p < 0.0001), and ciliary
                      body involvement (aHR = 0.77, $95\%-CI$ = 0.60-0.97, p =
                      0.029) were confirmed as independent predictors of LB in the
                      final multivariable Cox regression analysis.Approximately a
                      half of patients with large uveal melanoma develop LB around
                      2.5 years after brachytherapy. Further optimization of
                      treatment strategies, including both therapeutic and
                      preventive measures, has the potential to enhance the
                      functional outcome after episcleral plaque therapy for large
                      UMs.},
      keywords     = {106Ruthenium (Other) / 125Iodine (Other) / Bi-nuclide
                      plaque (Other) / Brachytherapy (Other) / Uveal melanoma
                      (Other) / Visual acuity (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39940039},
      doi          = {10.1186/s13014-024-02576-6},
      url          = {https://inrepo02.dkfz.de/record/298903},
}